BBV152
 | |
| Butiran vaksin | |
|---|---|
| Penyakit sasaran | SARS-CoV-2 |
| Jenis | Terinaktivasi |
| Data klinikal | |
| Nama dagang | Covaxin |
| Kaedah pemberian | Intraotot |
| Kod ATC | |
| Status perundangan | |
| Status perundangan |
|
| Pengecam | |
| DrugBank | |
BBV152 (juga disebut sebagai Covaxin) ialah vaksin COVID-19 yang mengandungi bahan berdasarkan virus tidak aktif. Vaksin tersebut dibangunkan oleh Bharat Biotech dengan kerjasama Badan Penyelidikan Perubatan India.[1][2][3][4][5][6]
Rujukan[sunting | sunting sumber]
- ^ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint (dalam bahasa Inggeris). 9 May 2020.
- ^ Chakrabarti A (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint.
- ^ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020.
- ^ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020.
- ^ Press, Associated (25 July 2020). "Asia Today: Amid new surge, India tests potential vaccine". Washington Post. Dicapai pada 17 December 2020.
- ^ "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express (dalam bahasa Inggeris). 25 July 2020.
Pautan luar[sunting | sunting sumber]
 |
Scholia mempunyai profil tentang BBV152 (Q98703813). |
- "How Bharat Biotech's Covaxin Vaccine Works". The New York Times.
.svg){kind=small}
Kategori:
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Vaksin COVID-19